CASIA OpenIR  > 中国科学院分子影像重点实验室
Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-Cu-64/IRDye800CW Allows Improved Breast Tumor Targeted Imaging and Therapy
Du, Yang1; Liang, Xiaolong2; Li, Yuan1,3; Sun, Ting1,3; Jin, Zhengyu3; Xue, Huadan3; Tian, Jie1
2017-11-01
发表期刊MOLECULAR PHARMACEUTICS
卷号14期号:11页码:3978-3986
文章类型Article
摘要The overexpression of programmed cell death-1 (PD 1) in tumors as breast cancer makes it a possible target for cancer imaging and therapy. Advances in molecular imaging, including radionuclide imaging and near-infrared fluorescence (NIRF) imaging, enable the detection of tumors with high sensitivity. In this study, we aim to develop a novel PD-1 antibody targeted positron emission tomography (PET) and NIRF labeled liposome loaded with doxorubicin (DOX) and evaluate its application for in vivo cancer imaging and therapy. IRDye800CW and Cu-60 were conjugated to liposomes with PD-1 antibody labeling, and DOX was inside the liposomes to form theranostic nanopartides. The 4T1 tumors were successfully visualized with PD-1-LiposomeDOX-Cu-64/IRDye800CW using NIRF/PET imaging. The bioluminescent imaging (BLI) results showed that tumor growth was significantly inhibited in the PD-1-Liposome-DOX-treated group than the IgG control. Our results highlight the potential of using dual-labeled theranostic PD-1 mAb-targeted Liposome-DOX-Cu-64/IRDye800CW for the management of breast tumor.
关键词Programmed Cell Death-i (Pd-i) Near-infrared Fluorescence (Nirf) Imaging Pet Imaging Doxorubicin (Dox) Breast Cancer Therapy
WOS标题词Science & Technology ; Life Sciences & Biomedicine
DOI10.1021/acs.molpharmaceut.7b00649
关键词[WOS]CELL LUNG-CANCER ; INFILTRATING LYMPHOCYTES ; ANTI-PD-L1 ANTIBODY ; DELIVERY-SYSTEMS ; POOR-PROGNOSIS ; CHEMOTHERAPY ; COMBINATION ; NIVOLUMAB ; EXPRESSION ; RESISTANCE
收录类别SCI
语种英语
项目资助者National Natural Science Foundation of China(81227901 ; Research and Development Program of China (973)(2014CB748600 ; Strategic Priority Research Program from Chinese Academy of Sciences(XDB02060010) ; Beijing Natural Science Foundation(Z16110200010000) ; Peking University Third Hospital(BYSY2015023) ; 81470083 ; 2015CB755500) ; 81527805 ; 81571810 ; 61231004 ; 81771846)
WOS研究方向Research & Experimental Medicine ; Pharmacology & Pharmacy
WOS类目Medicine, Research & Experimental ; Pharmacology & Pharmacy
WOS记录号WOS:000414820000034
引用统计
文献类型期刊论文
条目标识符http://ir.ia.ac.cn/handle/173211/19589
专题中国科学院分子影像重点实验室
作者单位1.Chinese Acad Sci, Key Lab Mol Imaging, State Key Lab Management & Control Complex Syst, Inst Automat, Beijing 100190, Peoples R China
2.Peking Univ, Hosp 3, Dept Ultrasound, Beijing 100191, Peoples R China
3.Beijing Union Med Coll Hosp, Dept Radiol, Beijing 100006, Peoples R China
推荐引用方式
GB/T 7714
Du, Yang,Liang, Xiaolong,Li, Yuan,et al. Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-Cu-64/IRDye800CW Allows Improved Breast Tumor Targeted Imaging and Therapy[J]. MOLECULAR PHARMACEUTICS,2017,14(11):3978-3986.
APA Du, Yang.,Liang, Xiaolong.,Li, Yuan.,Sun, Ting.,Jin, Zhengyu.,...&Tian, Jie.(2017).Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-Cu-64/IRDye800CW Allows Improved Breast Tumor Targeted Imaging and Therapy.MOLECULAR PHARMACEUTICS,14(11),3978-3986.
MLA Du, Yang,et al."Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-Cu-64/IRDye800CW Allows Improved Breast Tumor Targeted Imaging and Therapy".MOLECULAR PHARMACEUTICS 14.11(2017):3978-3986.
条目包含的文件 下载所有文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
Acs.molpharmaceut-du(4708KB)期刊论文作者接受稿开放获取CC BY-NC-SA浏览 下载
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Du, Yang]的文章
[Liang, Xiaolong]的文章
[Li, Yuan]的文章
百度学术
百度学术中相似的文章
[Du, Yang]的文章
[Liang, Xiaolong]的文章
[Li, Yuan]的文章
必应学术
必应学术中相似的文章
[Du, Yang]的文章
[Liang, Xiaolong]的文章
[Li, Yuan]的文章
相关权益政策
暂无数据
收藏/分享
文件名: Acs.molpharmaceut-du.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。